China Pharma Holdings, Inc. (CPHI)

NYSE: CPHI · Pharmaceutical Preparations · Hainan Province, CN · filing with the SEC since 2000

Full chart Alerts Compare

Grade3.5

◀ Past 2.1● Present 4.2▶ Future 3.8

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of China Pharma Holdings, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.5/10

◀ Past2.125% of the headline

● Present4.235% of the headline

▶ Future3.840% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

2.8/10

Has it survived what it has been through?

7 warning events since 2017; the latest 2026-04-01.

weight 22% of this tense · 27th percentile among 497 sector filers · read for itself

From the record

China Pharma Holdings, Inc.'s filings since 2017 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2023-10-03); an auditor change (8-K item 4.01, the latest 2024-05-08); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2026-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

2.3/10

What has it actually done, year after year?

-13.7% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 23rd percentile among 323 sector filers · read for its customers

From the record

China Pharma Holdings, Inc.'s 10 filed years say what it did: revenue went from $16 million in fiscal 2016 to $4 million in fiscal 2025, down 13.7% a year; it rose in 0 of 9 years; the deepest fall was 73% from fiscal 2016 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span-13.7%bottom 19% of its family
the share of years revenue rosebottom 4% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak73.4%bottom 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

1.3/10

How has it treated the people who own it?

SI estimate 1.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 13th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 13% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: China Pharma Holdings, Inc.'s shareholder treatment is put at 1.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 13% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.9/10

Is it financially healthy right now?

ROE -14%: lost 14¢ per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar.

weight 45% of this tense · 39th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, China Pharma Holdings, Inc. lost about 14 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 0 cents per dollar of everything the company owns. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 145.7% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 41% of its family
return on equitytop 23% of its family
gross profit against assetsbottom 2% of its family
the share count against the year beforebottom 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.7/10

How strong is its position in its industry?

bottom 37% of 315 in its family; net margin -76.9%.

weight 22% of this tense · 37th percentile among 315 sector filers · read for its customers

From the record

China Pharma Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 33% by size; a net margin of -76.9% ranks in the top 44%; revenue growth of -20% a year over the last 3 filed years ranks in the bottom 21% (its annual reports).

What it rests on

revenue against the family$4.1Mbottom 33% of its family
net margin-76.9%top 44% of its family
three-year revenue growth-20.0%bottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: No officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: China Pharma Holdings, Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.8/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

2.5/10

How much room does it have to grow?

bottom 25% of 273 in its family for room to expand.

weight 33% of this tense · 25th percentile among 273 sector filers · read for itself

From the record

China Pharma Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $345 thousand against no long-term debt tagged leaves 1.1% of its assets as net cash, bottom 15% of its family; cash from operations less capital spending is 2.1% of revenue (top 28%); a gross margin of -3.2% (bottom 3%); research spending of 6.8% of revenue (bottom 9%) (its annual report).

What it rests on

cash less debt against assets1.1%bottom 15% of its family
cash from operations less capital spending against revenue2.1%top 28% of its family
gross margin-3.2%bottom 3% of its family
research spending against revenue6.8%bottom 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.1/10

What could actually drive growth from here?

bottom 41% of 306 in its family for growth drivers.

weight 45% of this tense · 41st percentile among 306 sector filers · read for its customers

From the record

China Pharma Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -20% a year over the last three filed years against -13.7% over all 10, slowing (bottom 41% of its family); the newest year grew -8.5% (bottom 30%); research spending grew 14.8% a year (top 31%); capital spending grew -47.1% a year (bottom 23%) (its annual reports). China Pharma Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-6.4 points a yearbottom 41% of its family
the newest year's revenue growth-8.5%bottom 30% of its family
three-year growth of research spending14.8%top 31% of its family
three-year growth of capital spending-47.1%bottom 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.1/10

Did its newest year beat what its own record pointed to?

top 49% of 233 in its family for expectations against reality.

weight 22% of this tense · 51st percentile among 233 sector filers · read for its shareholders

From the record

China Pharma Holdings, Inc.'s newest year against its own record: revenue of $4 million in fiscal 2025 came in 22.4% above the $3 million its prior three years' pace pointed to (top 27% of its family); net income of $3 million against a prior three-year average of $4 million (top 48%); a net margin of -76.9% against -65.8% before (bottom 29%) (its annual reports).

What it rests on

revenue against the prior three years' pace22.4%top 27% of its family
net income against the prior three years' average+19%top 48% of its family
net margin against its prior average-11.1 pointsbottom 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton CPHI · research, not advice